中国抗生素耐药性治理的政策演变及启示

目的:本研究系统梳理了我国在不同时期实施的抗生素耐药性治理,分析政策的演变历程和原因,旨在为下一步政策制定提供启示。方法:在国家卫生健康委员会等相关部委的官方网站上,系统检索有关抗生素耐药性问题的政策文件,提取关键信息并梳理政策内容与时间节点,归纳和总结中国为应对抗生素耐药性问题所采取的政策和行动。结果:中国抗生素耐药性治理的政策演变过程可划分为三个阶段:以药品管控为主要治理策略的第一阶段,以临床监测为主要治理手段的第二阶段,多领域参与的全面治理策略的第三阶段。结论:为进一步解决抗生素耐药性问题,中国应加强社区感染控制和抗生素合理使用,加强对农业和环境领域的耐药性治理,建立基于"One Health"框架下的跨部门、跨学科合作平台,并加大抗生素替代药品的研发力度。     

Drug price,dosage and safety: Real-world evidence of oral hypoglycemic agents

ObjectivesDrug price reduction is one of the major policies to restrain pharmaceutical expenses worldwide. This study explores whether there is a relationship between drug price and clinical quality using real-world data.MethodsPatients with newly-diagnosed type 2 diabetes receiving metformin or sulfonylureas during 2001 and 2010 were identified using the claim database of the Taiwan universal health insurance system. Propensity score matching was performed to obtain comparable subjects for analysis. Pharmaceutical products were categorized as brand-name agents (BD), highpriced generics (HP) or low-priced generics (LP). Indicators of clinical quality were defined as the dosage of cumulative oral hypoglycemic agents (OHA), exposure to other pharmacological classes of OHA, hospitalization or urgent visit for hypoglycemia or hyperglycemia, insulin utilization and diagnosis of diabetic complications within 1 year after diagnosis.ResultsA total of 40,152 study subjects were identified. A generalized linear mix model showed that HP and BD users received similar OHA dosages with comparable clinical outcomes. By contrast, LP users had similar outcomes to BD users but received a 39% greater OHA dosage. A marginally higher risk of poor glycemic control in LP users was also observed.ConclusionsDrug price is related to indicators of clinical quality. Clinicians and health authorities should monitor the utilization, effectiveness and clinical safety indicators of generic drugs, especially those with remarkably low prices.     

Towards safe nurse staffing in England’s National Health Service: Progress and pitfalls of policy evolution

In 2013, a national inquiry into care failings at a large public hospital in England resulted in major healthcare reforms that included targeting policy aimed at ensuring the adequacy of nurse staffing levels on hospital wards within NHS England. This paper uses a review of publicly available documents to provide a contextual account of the evolution of nurse staffing policy development prior to and following the inquiry. We found that securing safe staffing policy has been impacted by caveats and competing policy, evidence gaps, lack of coordination, and the absence of readily implementable solutions. Consequently, five years on, safe staffing policy for NHS England is described in aspirational terms that ascribes accountability to providers, but fails to adequately address barriers to delivery. Kingdon’s ‘policy windows’ model is used to explain why policy, even when driven by strong public concern and with high inter-sector support, may struggle to gain traction when the conditions necessary for success are not present, and in the face of practical or political constraints. The progress and pitfalls encountered are not unique and the experience of safe staffing policy in England may have lessons for other countries grappling with policy development or implementation in this area.     

我国基层医疗机构卫生服务支付制度改革探讨

阐述了基本医疗卫生服务支付制度理论,梳理了我国基层医疗卫生机构卫生服务支付制度的现状,并对目前面临的主要问题加以分析.在此基础上,提出了相应的政策建议,一是遵循分类指导原则,调整政府对基层医疗卫生机构的财政支付方式;二是改革基本公共卫生服务经费支付方式,实行按项目付费的后付制;三是改革绩效工资制度,将对医务人员的支付与其服务数量和质量直接挂钩;四是设计以效果为导向的绩效考核指标,逐步提高按绩效支付比例;五是逐步整合医保门诊基金和基本公共卫生服务资金,实行按人头支付.     

国际全科医生制度发展历程:影响因素分析及政策启示

全科医生制度建设的国际经验可以为中国全科医生制度的建立和发展提供借鉴。本文首先梳理了国民健康服务体制、社会医疗保险体制、商业医疗保险体制等部分典型国家的全科医生制度发展历程,重点分析了全科医生制度建设的影响因素。结果发现,建立和发展全科医生制度的主要影响因素有:经济社会因素、卫生保健体制对卫生体系的控制力、医师对卫生体系的控制力、全科医学服务的激励机制、全科医学的发展程度等。最后,结合近年我国全科医生制度建设的实际提出几点政策启示,一要以满足我国公众健康需求为目标,构建中国特色全科医生制度;二要普及全科医学服务核心价值,为建立全科医生制度提供公众民意基础;三要建立健全促进全科医生制度发展的激励机制,提高全科医生地位;四要积极推动全科与专科医学的专业分工,促进全科医学发展。     

关于缩短医院平均住院日的探讨

为充分利用医疗资源,降低患者住院的总体医药费用,缓解大型三甲综合性医院看病贵、看病难的问题,缩短平均住院日是有效的途径之一。医院实施临床路径管理、加强平均住院日管理、压缩检查化验等候时间、技术创新和诊治创新、开展"双向转诊"服务、改变患者传统看病治病意识等措施,能达到缩短平均住院日的目的。     

Health benefits,safety and cost of physical activity interventions for mental health conditions: A meta-review to inform translation efforts

BackgroundMental illness is a leading cause of the global burden of disease. Physical activity (PA) can improve physical and mental health outcomes for people with mental illness, yet routine implementation of PA within standard care remains ad-hoc. The reasons for this are unclear, although the dissonance between the evidence produced in research settings and that needed in real-world environments may be key.PurposeTo explore the effectiveness of PA interventions as a treatment for mental illness. We synthesised past systematic reviews and meta-analyses.MethodsWe conducted a systematic review of reviews from database inception to 09/2017. Reviews were included that considered any mental health condition (diagnosed via standardised criteria) and where PA interventions were a stand-alone or adjunctive treatment. Effectiveness was defined as outcomes that are important in real-world healthcare (i.e. expected clinical outcomes, intervention safety and cost).ResultsFrom 4008 hits, 33 reviews (including 155 unique studies) were included and 32 reported that PA has a positive effect on at least one main outcome of interest (symptoms of mental illness, quality of life and/or physical health). There was inconsistent reporting of adverse events and no cost data was identified. The AMSTAR quality rating suggests inconsistencies in review quality.ConclusionsThe research agenda must expand to report on outcomes that can support evidence translation efforts (i.e. cost and adverse events). Without such a shift, research in PA and mental health may fail to achieve translation to routine care and may have limited impact on patient outcomes.     

Progress toward sustainable influenza vaccination in the Lao Peoples’ Democratic Republic, 2012–2018

Despite global recommendations for influenza vaccination of high-risk, target populations, few low and middle-income countries have national influenza vaccination programs. Between 2012 and 2017, Lao PDR planned and conducted a series of activities to develop its national influenza vaccine program as a part of its overall national immunization program. In this paper, we review the underlying strategic planning for this process, and outline the sequence of activities, research studies, partnerships, and policy decisions that were required to build Laos’ influenza vaccine program. The successful development and sustainability of the program in Laos offers lessons for other low and middle-income countries interested in initiating or expanding influenza immunization.     

Supporting national immunization technical advisory groups (NITAGs) in resource-constrained settings. New strategies and lessons learned from the Task Force for Global Health’s Partnership for influenza vaccine introduction

National Immunization Technical Advisory Groups (NITAGs) are multidisciplinary national experts who provide independent, evidence-informed vaccine policy recommendations to national health authorities. An essential NITAG function is to ensure that these decisions are grounded in the best available evidence generated through a systematic, transparent process. However, in many low- and middle-income countries (LMICs), experience with this decision making method is limited. The Task Force for Global Health manages the Partnership for Influenza Vaccine Introduction (PIVI) program in collaboration with the Centers for Disease Control and Prevention, Ministries of Health, corporate partners and others. During 2017, PIVI worked with its country partners and the World Health Organization regional and local offices to assess NITAG strengthening needs and to provide technical assistance in 7 LMIC countries (Laos Peoples Democratic Republic, Mongolia, Vietnam, Armenia, Côte d’Ivoire; Moldova and the Republic of Georgia). Our workshops supported general NITAG capacity building and the evidence-based review process using vaccines of interest to the country. For NITAGs reviewing evidence on seasonal influenza, we developed an influenza resource package to support their review and provide country-relevant information in an easy to use format. Of the seven NITAGs trained, six have applied some of the concepts learnt: revision or development of formal transparent, systematic procedures for their operations; preparation of recommendations on seasonal influenza vaccination using quality-assessed data from systematic searches and local data; and have applied the principles learned for making other new vaccine recommendations. Our experience confirms that LMIC NITAGs are considerably under-resourced without adequate technical support or access to global peer-reviewed literature. Ongoing support from NITAG partners must be secured and creative approaches might be needed to help countries achieve the GVAP 2020 target and support development of sustainable vaccine policies and programs.     

Immunisation of migrants in EU/EEA countries: Policies and practices

In recent years various EU/EEA countries have experienced an influx of migrants from low and middle-income countries. In 2018, the “Vaccine European New Integrated Collaboration Effort (VENICE)” survey group conducted a survey among 30 EU/EEA countries to investigate immunisation policies and practices targeting irregular migrants, refugees and asylum seekers (later called “migrants” in this report). Twenty-nine countries participated in the survey. Twenty-eight countries reported having national policies targeting children/adolescent and adult migrants, however vaccinations offered to adult migrants are limited to specific conditions in seven countries. All the vaccinations included in the National Immunisation Programme (NIP) are offered to children/adolescents in 27/28 countries and to adults in 13/28 countries. In the 15 countries offering only certain vaccinations to adults, priority is given to diphtheria-tetanus, measles-mumps-rubella and polio vaccinations. Information about the vaccines given to child/adolescent migrants is recorded in 22 countries and to adult migrants in 19 countries with a large variation in recording methods found across countries. Individual and aggregated data are reportedly not shared with other centres/institutions in 13 and 15 countries, respectively. Twenty countries reported not collecting data on vaccination uptake among migrants; only three countries have these data at the national level. Procedures to guarantee migrants’ access to vaccinations at the community level are available in 13 countries. In conclusion, although diversified, strategies for migrant vaccination are in place in all countries except for one, and the strategies are generally in line with international recommendations. Efforts are needed to strengthen partnerships and implement initiatives across countries of origin, transit and destination to develop and better share documentation in order to guarantee a completion of vaccination series and to avoid unnecessary re-vaccination. Development of migrant-friendly strategies to facilitate migrants' access to vaccination and collection of vaccination uptake data among migrants is needed to meet existing gaps.